Detalles de la búsqueda
1.
Increasing Rates of RSV Hospitalization among Preterm Infants: A Decade of Data.
Am J Perinatol
; 40(14): 1529-1536, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34704241
2.
Effectiveness and Safety of Palivizumab for the Prevention of Serious Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus: A Systematic Review.
Am J Perinatol
; 2023 Jan 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-36452969
3.
Respiratory Syncytial Virus and All-Cause Bronchiolitis Hospitalizations Among Preterm Infants Using the Pediatric Health Information System (PHIS).
J Infect Dis
; 225(7): 1197-1204, 2022 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32691037
4.
RSV-related hospitalization and outpatient palivizumab use in very preterm (born at <29 wGA) infants: 2003-2020.
Hum Vaccin Immunother
; 18(6): 2140533, 2022 Nov 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-36412253
5.
Healthcare resource utilization and costs in the 12 months following hospitalization for respiratory syncytial virus or unspecified bronchiolitis among infants.
J Med Econ
; 23(2): 139-147, 2020 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-31432723
6.
Trends in Utilization of Outpatient Respiratory Syncytial Virus Prophylaxis with Palivizumab among Medicaid- and Commercially Insured Infants.
Infect Dis Ther
; 7(1): 121-134, 2018 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-29149439
Resultados
1 -
6
de 6
1
Próxima >
>>